Supplements for ALS Support: What Evidence Exists

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease affecting motor neurons in the brain and spinal cord, leading to paralysis and ultimately respiratory failure. With only a handful of approved treatments offering modest benefit — riluzole, edaravone, and sodium phenylbutyrate-taurursodiol (AMX0035) — patients and caregivers often look to nutritional support as adjuncts. The honest assessment of supplement evidence in ALS is one of potential but frequent failure in clinical trials.

Creatine: Failed But Not Dismissed

Creatine monohydrate was one of the most promising candidates for ALS given its role in cellular energy metabolism and neuroprotection in animal models. Multiple ALS mouse model studies showed dramatic survival benefits with creatine supplementation. Three large randomized controlled trials in ALS patients (NEALS creatine trial, and others) with doses ranging from 5 to 30 grams daily ultimately found no benefit in slowing disease progression or survival.

Despite these failures, creatine remains commonly used by ALS patients and is not harmful. The disconnect between animal model success and human trial failure is a recurring problem in ALS research, partly attributable to differences in disease mechanism between mouse models and human ALS. Creatine may still support muscle energy metabolism in a disease characterized by muscle wasting, though proving this has been elusive.

Omega-3 Fatty Acids

Higher caloric intake and fat intake are associated with slower ALS progression in epidemiological studies, and omega-3 fatty acids may play a role. A Harvard prospective study found higher intake of omega-3 polyunsaturated fatty acids associated with reduced ALS risk. DHA and EPA reduce neuroinflammation — a component of ALS pathology — and DHA supports motor neuron membrane integrity.

A high-calorie, high-fat diet (including omega-3 enriched formulas) has been evaluated in ALS with some positive results for stabilizing weight — a critical prognostic marker in ALS where weight loss predicts faster decline. Omega-3 supplementation at 3 to 4 grams daily is a reasonable nutritional support measure given its benign safety profile and epidemiological support.

CoQ10

CoQ10 addresses mitochondrial dysfunction and oxidative stress, both documented in ALS. A 2004 randomized phase II trial tested 1,800 mg/day CoQ10 in ALS patients over 9 months. The trial found a trend toward slowing decline but did not reach statistical significance in its primary endpoint — classifying it as a negative trial, though the trend was noted as hypothesis-generating. The trial was not powered to detect the effect size seen.

Given its safety profile and mechanistic rationale (mitochondrial support is relevant in ALS), CoQ10 at 600 to 1,200 mg daily remains a reasonable consideration for supportive care.

Vitamin E

Vitamin E is a lipid-soluble antioxidant that protects neuronal cell membranes from oxidative damage. Prospective studies find that individuals with higher vitamin E intake have a modestly lower risk of developing ALS. As with other antioxidants, animal model data was promising and led to clinical trials. A pilot randomized trial of vitamin E (5,000 mg/day alpha-tocopherol, a very high dose) combined with riluzole found no benefit in slowing progression compared to riluzole alone.

Mixed tocopherols (including gamma-tocopherol) may be preferable to high-dose alpha-tocopherol alone, as high-dose alpha-tocopherol supplementation has shown paradoxical effects in other oxidative stress conditions. Standard antioxidant doses (400 to 800 IU mixed tocopherols) are lower risk than the 5,000 mg trial doses.

Riluzole Interactions Note

Riluzole is the oldest approved ALS treatment and is metabolized by the liver enzyme CYP1A2. Supplements that significantly induce or inhibit CYP1A2 could theoretically affect riluzole levels. Cruciferous vegetables and smoked meats are known CYP1A2 inducers. Most commonly used supplements do not have significant CYP1A2 interactions, but this pathway should be considered when evaluating unusual botanicals alongside riluzole. Standard supplements like omega-3, CoQ10, and creatine do not have documented riluzole interactions.

Nutritional Support as a Priority

Beyond specific supplements, maintaining caloric intake is a primary goal in ALS care. Dysphagia and muscle wasting create caloric deficits that worsen prognosis. High-calorie nutritional support — including healthy fats, protein, and micronutrient-dense foods — may slow the weight loss trajectory. Supplements should be viewed within this broader nutritional support context.

FAQ

Q: Why do supplements that work in mouse ALS models fail in humans?

ALS in mice (typically SOD1 mutations) has different pathophysiology from the heterogeneous human disease. Interventions in end-stage mouse disease may not translate to the earlier or different pathological stages in humans. This failure mode affects pharmaceutical trials as well, not just supplements.

Q: Is there any supplement with proven benefit in ALS?

No supplement has demonstrated proven benefit in large randomized controlled trials in ALS. This is an honest and important distinction from conditions where supplement evidence is stronger.

Q: What supplements are most often used by ALS patients?

Beyond creatine and CoQ10, vitamin D (commonly deficient in ALS patients), B vitamins, and omega-3 fatty acids are frequently used. Maintaining vitamin D in the 50 to 70 ng/mL range is a reasonable supportive goal.

Q: Does riluzole interact with fish oil?

There are no documented pharmacokinetic interactions between omega-3 fish oil and riluzole. Both can be taken together safely based on available data.

Track your supplements in Optimize.